Immunocore Holdings PLC ADR
Uždarymo kaina
32.4 -2.94
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
32.4
Max
32.84
Pajamos | -14M -786K |
|---|---|
Pardavimai | 9.3M 116M |
Pelnas, tenkantis vienai akcijai | -0.02 |
Pelno marža | -0.678 |
Darbuotojai | 524 |
EBITDA | -13M 3.6M |
Kitas uždarbis | 2026-11-05 |
|---|
Rinkos kapitalizacija | 211M 1.9B |
|---|---|
Ankstesnė atidarymo kaina | 35.34 |
Ankstesnė uždarymo kaina | 32.4 |
Immunocore Holdings PLC ADR Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Immunocore Holdings PLC ADR Prognozė
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę Immunocore Holdings PLC ADR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.